Trial Profile
A phase II study of sunitinib malate [sunitinib] in combination with capecitabine in patients with advanced or metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 30 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.